These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 35061196)
1. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Serrano C; Bauer S Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196 [TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors (GIST)]. Jaros D; Bozic B; Sebesta C Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864 [TBL] [Abstract][Full Text] [Related]
3. New treatments in advanced gastrointestinal stromal tumor. Serrano C Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479 [TBL] [Abstract][Full Text] [Related]
4. [Advanced GIST: Which treatments in 2022?]. Mas L; Bachet JB Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543 [TBL] [Abstract][Full Text] [Related]
5. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with George S; Blay JY; Chi P; Jones RL; Serrano C; Somaiah N; Gelderblom H; Zalcberg JR; Reichmann W; Sprott K; Cox P; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S Future Oncol; 2024; 20(27):1973-1982. PubMed ID: 39229786 [TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the treatment of gastrointestinal stromal tumors. Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383 [TBL] [Abstract][Full Text] [Related]
7. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525 [TBL] [Abstract][Full Text] [Related]
8. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem. Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849 [TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal stromal tumor: a review of current and emerging therapies. Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372 [TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Mohammadi M; Gelderblom H Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274 [No Abstract] [Full Text] [Related]
11. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265 [TBL] [Abstract][Full Text] [Related]
12. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. Schaefer IM; DeMatteo RP; Serrano C Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35522913 [TBL] [Abstract][Full Text] [Related]
13. New therapeutic agents in gastrointestinal stromal tumours. Falkenhorst J; Hamacher R; Bauer S Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566 [TBL] [Abstract][Full Text] [Related]
14. Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in PDGFRA D842V-Mutant Gastrointestinal Stromal Tumor. Rossi F; Liu M; Tieniber A; Etherington MS; Hanna A; Vitiello GA; Param NJ; Do K; Wang L; Antonescu CR; Zeng S; Zhang JQ; DeMatteo RP Clin Cancer Res; 2023 Jun; 29(11):2144-2157. PubMed ID: 36971786 [TBL] [Abstract][Full Text] [Related]
15. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758 [TBL] [Abstract][Full Text] [Related]
16. Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval. Goggin C; Stansfeld A; Mahalingam P; Thway K; Smith MJ; Huang P; Jones RL; Napolitano A Future Oncol; 2022 Aug; 18(26):2967-2978. PubMed ID: 35880452 [TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs? Senchak J; Ahr K; von Mehren M Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049 [TBL] [Abstract][Full Text] [Related]
18. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS). Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409 [TBL] [Abstract][Full Text] [Related]
19. Next questions for the medical treatment of gastrointestinal stromal tumor. Italiano A Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519 [TBL] [Abstract][Full Text] [Related]
20. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Smrke A; Gennatas S; Huang P; Jones RL Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]